Revolution Medicines Inc.
Clinical-stage precision oncology firm targeting RAS-addicted cancers with multiple RAS(ON) inhibitors (e.g., RMC-6236, RMC-6291) and companion agents, all in Phase 1/2 trials, backed by a Sanofi collaboration.
Headquarters: United States (USA)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Hospitals and Health Care
- Industry: Medical Practices
- Employees: 809
- HQ: Redwood City
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.